Item 8.01 Other Events.
On February 12, 2009, La Jolla Pharmaceutical Company (the "Company") issued a
press release announcing that an Independent Data Monitoring Board for the
Riquent® Phase 3 ASPEN study has informed the Company that they have completed
the first interim efficacy analysis and determined that continuing the study is
futile. The Company has decided to stop the study, unblind the data and evaluate
the results. The Company also reported that it expects to provide additional
guidance on its strategic options going forward in the near future.
Top of the Form
Add
LJPC to Portfolio
Set Alert
Email to a
Friend